...
首页> 外文期刊>International Journal of Biomedical Science >Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia
【24h】

Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia

机译:异体造血细胞移植治疗急性早幼粒细胞白血病后17年,供体细胞来源的急性髓性白血病

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Donor cell leukaemia (DCL) is a rare complication of allogenic hematopoietic cell transplantation (HCT). We report the case of a female patient with acute promyelocytic leukaemia (APL), FAB type M3, who developed acute myeloid leukaemia (AML) type M5 of donor origin 17 years after allogenic bone marrow transplantation (BMT) from her HLA-matched sister. Morphology and immunophenotyping showed differences with the initial leukaemia, and short tandem repeat (STR) analysis confirmed donor-type haematopoiesis. Interphase fluorescence in situ hybridisation (FISH) showed an 11q23 deletion. Given that the latency period between transplant and development of leukaemia was the longest reported to date, we discuss the mechanisms underlying delayed leukaemia onset.
机译:供体细胞白血病(DCL)是同种异体造血细胞移植(HCT)的罕见并发症。我们报道了一名女性患者,该患者患有急性早幼粒细胞白血病(APL),M3型FAB,在她的HLA配对姐妹进行了同种异体骨髓移植(BMT)后17年发展了供体来源的急性髓性白血病(AML)M5型。形态学和免疫表型分析显示与最初的白血病有所不同,短串联重复序列(STR)分析证实了供体型造血功能。相间荧光原位杂交(FISH)显示11q23缺失。鉴于迄今报道的白血病移植和发展之间的潜伏期是迄今为止最长的,因此我们讨论了延迟白血病发作的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号